| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9320407 | European Urology | 2005 | 9 Pages |
Abstract
Chronic therapy with TAD improves endothelial function in patients with increased cardiovascular risk regardless their degree of ED. The benefit of this therapy is sustained for at least two weeks after the discontinuation of therapy. Larger studies are needed in order to assess the possible clinical implications of chronic therapy with TAD.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Giuseppe M.C. Rosano, Antonio Aversa, Cristiana Vitale, Andrea Fabbri, Massimo Fini, Giovanni Spera,